{"ticker": {"uuid": "b9bb7bef-e478-4ef9-ada9-0036dc78ff25", "symbol": "FULC", "name": "Fulcrum Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about its benefit-risk profile. The FDA concluded that a", "url": "https://www.newmediawire.com/news/fulcrum-therapeutics-inc-nasdaq-fulc-faces-possible-securities-law-violations-contact-kaplan-fox-kilsheimer-llp-7087255", "source_name": "NewMediaWire", "published_at": "2026-06-20T12:39:48", "published_display": "20 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding a potential malignancy risk associated with PRC2 inhibition. Fulcrum announced it would discontinue the development", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1173566", "source_name": "ACCESS Newswire", "published_at": "2026-06-19T20:39:29", "published_display": "19 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's be", "url": "https://markets.financialcontent.com/stocks/article/thenewswire-2026-6-19-kaplan-fox-encourages-investors-of-fulcrum-therapeutics-inc-nasdaq-fulc-to-contact-the-firm", "source_name": "FinancialContent", "published_at": "2026-06-19T10:30:00", "published_display": "19 Jun 2026 10:30", "sentiment": "negative", "sentiment_pct": 10, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). This investigation follows the company's announcement of discontinuing its pociredir program for sickle cell disease due to heightened FDA concerns ", "url": "https://www.newmediawire.com/news/investors-of-fulcrum-therapeutics-inc-nasdaq-fulc-are-encouraged-to-contact-kaplan-fox-regarding-the-investigation-of-potential-securities-law-violations-7087218", "source_name": "NewMediaWire", "published_at": "2026-06-18T15:12:11", "published_display": "18 Jun 2026 15:12", "sentiment": "negative", "sentiment_pct": 12, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Fulcrum Therapeutics Inc (FULC) has an earnings forecast score of 5.78, ranking 337th in the Biotechnology & Medical Research industry. Analysts have an average price target of $20.00, with a range of $5.00 to $25.00. Based on ratings from 9 analysts, the consensus is to \"Hold\" F", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fulc/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:14", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9wQ0ZweHRoeFdUOFRzZjhXdkI1LW51ZWxLUXVJTjlzb1hkNVJiampYZTJMN0xtaGNobzJGM3ZReXhjZGRCMWxWM3AwSlRPdlFFVV9KYmE3clExX3FqS0NLbmlqMnN4bnMtalc5bGpKMFRmcEhZNHQ4?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T06:08:38+00:00", "published_display": "18 Jun 2026 06:08", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's ben", "url": "https://www.newmediawire.com/news/kaplan-fox-reminds-investors-of-fulcrum-therapeutics-inc-nasdaq-fulc-to-an-investigation-of-potential-securities-law-violations-7087193", "source_name": "NewMediaWire", "published_at": "2026-06-17T18:40:05", "published_display": "17 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) after the company disclosed concerns from the U.S. FDA regarding a malignancy risk with its lead candidate, pociredir, leading to its discontin", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/fulcrum-therapeutics-inc.-fulc-investigation-bronstein-gewirtz-a-1173565", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T11:00:00", "published_display": "17 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the major shareholder structure and institutional holdings of Fulcrum Therapeutics Inc (FULC). It lists the top individual shareholders and classifies shareholders by type, such as hedge funds and investment advisors. The report also provides a historical ove", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fulc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T06:11:44", "published_display": "17 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan F", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about its benefit-risk profile and malignancy risk. Following this announcement o", "url": "https://natlawreview.com/press-releases/fulcrum-therapeutics-investors-are-encouraged-contact-kaplan-fox-kilsheimer", "source_name": "The National Law Review", "published_at": "2026-06-16T23:10:33", "published_display": "16 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) securities. This investigation follows Fulcrum's disclosure that the FDA raised concerns about a potential malignancy risk with PRC2 inhibition", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/fulcrum-therapeutics-inc.-fulc-investigation-bronstein-gewirtz-a-1173563", "source_name": "ACCESS Newswire", "published_at": "2026-06-15T11:00:00", "published_display": "15 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding malignancy risk associated with PRC2 inhibition. Fulcrum announced the discontinuation of", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-fulcrum-ther-1173562", "source_name": "ACCESS Newswire", "published_at": "2026-06-14T11:00:00", "published_display": "14 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Fulcrum Therapeutics, Inc. (FULC) on behalf of investors. This investigation follows Fulcrum's disclosure of FDA concerns about a potential malignancy risk associated with PRC2 inhibition, leading the co", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-fulcrum-therapeuti-1173561", "source_name": "ACCESS Newswire", "published_at": "2026-06-12T16:39:12", "published_display": "12 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart", "summary": "Fulcrum Therapeutics has implemented special retention and change-in-control protections for its remaining leadership following a major restructuring tied to discontinuing the development of pociredir for sickle cell disease. CEO Alex C. Sapir, Chief Legal Officer Curtis Oltmans,", "url": "https://www.stocktitan.net/sec-filings/FULC/8-k-fulcrum-therapeutics-inc-reports-material-event-978f654725aa.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:43", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tang entities report 5,451,800\u2011share stake in Fulcrum (FULC)", "summary": "Tang Capital Management and affiliated entities have reported a combined stake of 5,451,800 shares, representing 8.2% of Fulcrum Therapeutics (FULC) common stock. This beneficial ownership involves shared voting and dispositive power among the Tang group, as detailed in a Schedul", "url": "https://www.stocktitan.net/sec-filings/FULC/schedule-13g-fulcrum-therapeutics-inc-passive-investment-disclosure-5-5d0c8a2037d8.html", "source_name": "Stock Titan", "published_at": "2026-06-10T22:39:49", "published_display": "10 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. The decision came after FDA concerns regarding the drug's benefit-ris", "url": "https://www.newmediawire.com/news/kaplan-fox-is-investigating-potential-securities-law-violations-against-fulcrum-therapeutics-inc-nasdaq-fulc-7087107", "source_name": "NewMediaWire", "published_at": "2026-06-10T18:39:49", "published_display": "10 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after its shares dropped by approximately 50% following a disclosure that the FDA raised safety concerns regarding PRC2 inhibition. The company subsequently discontinued its lead sickle cell disease ", "url": "https://www.prnewswire.com/news-releases/fulcrum-therapeutics-inc-fulc-securities-fraud-investigation---levi--korsinsky-302789808.html", "source_name": "PR Newswire", "published_at": "2026-06-10T05:40:38", "published_display": "10 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) after the company announced it was discontinuing the development of its lead candidate, pociredir, due to FDA concerns about a potential malignancy ri", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/fulcrum-therapeutics-inc.-fulc-investigation-bronstein-gewirtz-a-1173558", "source_name": "ACCESS Newswire", "published_at": "2026-06-09T11:00:00", "published_display": "09 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum plunges after discontinuing lead program", "summary": "Fulcrum Therapeutics announced it is discontinuing the development of its lead program, losmapimod, for facioscapulohumeral muscular dystrophy (FSHD) after it failed to meet its primary endpoint in a Phase 3 trial. This decision led to a significant drop in its stock price and a ", "url": "https://www.msn.com/en-us/health/other/fulcrum-plunges-after-discontinuing-lead-program/ar-AA24DFfe?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-08T09:39:37", "published_display": "08 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)", "summary": "Levi & Korsinsky has initiated an investigation into the officers and directors of Fulcrum Therapeutics, Inc. (FULC) following a significant stock collapse. The investigation stems from the company's discontinuation of its pociredir program due to FDA safety concerns, despite pri", "url": "https://www.prnewswire.com/news-releases/fulcrum-therapeutics-inc-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc-302789096.html", "source_name": "PR Newswire", "published_at": "2026-06-06T07:39:18", "published_display": "06 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Fulcrum Therapeutics Stock On Thursday?", "summary": "Fulcrum Therapeutics stock experienced volatility on Thursday after the company discontinued its lead experimental sickle cell disease drug, pociredir, due to FDA concerns about malignancy risks. This decision followed FDA interactions highlighting risks similar to another PRC2 i", "url": "https://www.sahmcapital.com/news/content/whats-going-on-with-fulcrum-therapeutics-stock-on-thursday-2026-06-04", "source_name": "Sahm", "published_at": "2026-06-06T03:39:49", "published_display": "06 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks", "summary": "Fulcrum Therapeutics has discontinued its clinical-stage program for pociredir, a sickle cell disease treatment, after the FDA raised concerns about potential malignancy risks associated with its mechanism of action. This decision follows the withdrawal of Ipsen\u2019s similar drug, T", "url": "https://www.fiercebiotech.com/biotech/fulcrum-scraps-scd-program-considers-options-after-fda-takes-hard-line-safety-risks", "source_name": "Fierce Biotech", "published_at": "2026-06-05T19:10:30", "published_display": "05 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives", "summary": "Fulcrum Therapeutics is laying off 85% of its workforce, notifying employees on Thursday. The Cambridge biotech has enlisted Leerink Partners to explore strategic alternatives such as a merger or acquisition. This move comes as the company navigates its future options.", "url": "https://www.bizjournals.com/boston/news/2026/06/05/fulcrum-therapeutics-cuts-85-workforce.html", "source_name": "The Business Journals", "published_at": "2026-06-05T17:39:14", "published_display": "05 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)", "summary": "Levi & Korsinsky, LLP has announced an investigation into potential securities claims against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant 50% stock drop. This plunge occurred after Fulcrum disclosed that the FDA raised class-wide safety concerns about PRC2-t", "url": "https://www.globenewswire.com/news-release/2026/06/05/3307390/3080/en/levi-korsinsky-announces-investigation-of-securities-claims-against-fulcrum-therapeutics-inc-fulc.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T12:59:31", "published_display": "05 Jun 2026 12:59", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOcDFpNDVVUm5CYXJBN25vWmpNVEs1VW44b1JkeWZ5WGcxRXNvRkQtNWE2MEkwTnhhN0lVOWJVZUc0M0J6UjAtMWhsWmUtaW5VVUI1bmVYcnkwc0NlQWtFdWFxTWhpaExUUzBMdHAycm5UbnduRDNHaTktdFpxRHFwLTYxNF9OSlZSd2o4d3RMaGdlWmZVZ1hvVVFiWE1yV0Fy?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad Review", "summary": "Fulcrum Therapeutics (FULC) is undergoing a significant re-evaluation after halting its sickle cell drug pociredir due to FDA concerns, leading to a 52.5% drop in share price over seven days. While some narratives suggest the stock is undervalued at $3.22, with a fair value estim", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fulc/fulcrum-therapeutics/news/a-look-at-fulcrum-therapeutics-fulc-valuation-after-halting", "source_name": "Simply Wall Street", "published_at": "2026-06-05T00:09:34", "published_display": "05 Jun 2026 00:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review", "summary": "Fulcrum Therapeutics is undergoing a major restructuring, reducing its workforce by 85% (from 57 to 9 employees) and incurring $4.2 million in related charges, primarily due to the discontinuation of its sickle cell disease program, pociredir. The company has engaged Leerink Part", "url": "https://www.stocktitan.net/sec-filings/FULC/8-k-fulcrum-therapeutics-inc-reports-material-event-753ddc1bbccf.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:09:34", "published_display": "04 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud", "summary": "Levi & Korsinsky is investigating Fulcrum Therapeutics, Inc. (FULC) for potential securities fraud after its stock plunged approximately 50% on June 1, 2026. This drop followed the company's disclosure of FDA safety concerns related to its PRC2 inhibitor drug class, leading to th", "url": "https://www.businesswire.com/news/home/20260604159988/en/FULC-Investor-Alert-Levi-Korsinsky-Investigates-Fulcrum-Therapeutics-Inc.-FULC-for-Potential-Securities-Fraud", "source_name": "Business Wire", "published_at": "2026-06-04T19:09:34", "published_display": "04 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring", "summary": "Fulcrum Therapeutics (FULC) has shown sharp volatility after discontinuing its lead sickle cell drug, pociredir, and undergoing a major restructuring. While analysts suggest the stock is undervalued at $3.37 with a fair value of $19 based on future growth, Simply Wall St's DCF mo", "url": "https://finance.yahoo.com/sectors/healthcare/articles/look-fulcrum-therapeutics-fulc-valuation-151530350.html", "source_name": "Market source", "published_at": "2026-06-04T06:40:05", "published_display": "04 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations", "summary": "SueWallSt is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company's stock dropped approximately 50% following an FDA disclosure regarding class-wide safety concerns for PRC2-targeting agents, which led to the discontinu", "url": "https://www.morningstar.com/news/pr-newswire/20260603ny74176/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations", "source_name": "Morningstar", "published_at": "2026-06-03T15:09:25", "published_display": "03 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-downgrades-fulcrum-therapeutics-underweight-112848485.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:28:48+00:00", "published_display": "03 Jun 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug", "summary": "", "url": "https://finance.yahoo.com/m/936c99ae-f8d5-3e0a-831d-d476317640c5/fulcrum-exploring-a-potential.html", "source_name": "BioPharma Dive", "published_at": "2026-06-02T12:08:00+00:00", "published_display": "02 Jun 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink downgrades Fulcrum Therapeutics stock rating on FDA concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQOVMyUmhWMFFXOExEZF9SVmVrbFlycnBEWHZNU081TFgxWXZaT0FkelU1elVKWGJ2RUdVekxWdC1jUTBNWXFuTlZ1ZmFrekNMX3JPQlZKNGt0dnZoRW1JLWEwS3I5X2pzMERvb1FyOU10dTR1VnFTN0lrRDdNd2VDVEYwVEhxYzZkb19PcHZzeVZXX3E2OVFsRjV3MWFhSlJvR2hONlhMM1hLekdQQU9EN0F1Vk0tNGYxWk4zdmtrbEVFOGZGTHUw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Fulcrum Therapeutics stock collapsing today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNUk9EVUc4dl9Eb2hzWnpXeXVxbHhhRG52ZWZPWWd6cVJQQy1SVDhFY3k1OUhuYzFja25IN3gtWkRva1A5SmZXRkUzTTI5dkxnaktSUHVuajktMVZBRm96VXJ6TXJiQ2ctNUdLaFMyZlJIUFRLeG1SMGpTOE5Xeng0Ml9zTUUtOEo3YlBRRkdNY0tscEtydC1remVIZUQ3eEVfUkVjNzF4V2tuQU5QbXczSjZR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright downgrades Fulcrum stock rating on FDA concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNa3pBNEhSS3hSQWRhVDdsTUF1cm8yX1pXNVlYZnpSaEFvTDI5VFQwclp1VDIwSFFacEphNWRHd3ZjbHFUaXVEbEJ0a18ydWwxbllvZjdMektjbW5NWU9xVDVyVnMwVTFUcmpjN1NEQk9Ib0RMN1IwM2xOY19wMTdTTlZJVVh3Z2R1LVY1T0FkRE5XQ3pEN1AtdW93clBJX2diTVZock02T3AzWmNvaDJqRW81bVVMeW9DYjIyNUVR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum drops work on SCD drug pociredir; stock plummets", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOSTdYZW8xZ2R2R0RoRzBZWmNuNldHUjZheE81Y0VLWVhXYjY2bXVER1lwMkhLcWNZWVRFNjV5dTdBcXc0T2YtaWFLazVMbS04SWNpZlZpb040NFdqc1N3T3JwOTlrMmg2Z01XWnBYbGsxTXU3QjV3d1NvTHFybDhNMmFNR0prTFZKTFZkdzg0cHRjMkxvcU1qLWxmb1I?oc=5", "source_name": "BioWorld News", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOaUtrTTZXbU9VNlN4Umc5TUFWMVVWd1lvWDBUYm9BbUpjSll5WFFscHJ2Zl9GbGw5LVRPQ0IwUFVWbjQwRWFzVHNfeEhfUmhjams3SUlfSmpOY0p5U1dQRzk0c2c3QUhUa0M0RnFTNXc3LVllOWNOUUNTU0hEY2l6SjljTzFqa1o4dW5zTnRrR3VtREZON1hHNmdLYXA2dTQtbzFQOVo3ZEFsSTlFU2paZ3lzbUhCWHlnbFNFS0gxUWZVS2NiWmI4ZXh5bno4ZUN1UFlic3VmVl9GTDJfNkNmdnpKZlpBUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA cancer-risk stance ends sickle cell drug; Fulcrum weighs options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOakRpb1o1WXVqcThrWGdzYnp1eXlvazEyQnRpdWVWWjR5QmtkaEEtZno2SmpUN3NzSnhGZGVyaHQtbzlPa3JFQ1dYX05EZHdBOEFuNXlsc05tLTBhTTVESHRBWVRTeEZmclhDR3dQOFV0V3dBaWlmY202dU5jYmc5eDY4OWdTckU2Yld6SGJHVVpZNkkyVTlraWpQejlLQXJtUmQtaUhsVF9taUJBaXlUNTh3RGVwTWtpOWVMcjVvOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "After sickle cell data, Fulcrum plans late-2026 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQenF3VDk1SHhMUlhhWnhfY09TZXJOZzUya2JYV0FhMTc2TTdkWkw1RWpLdWhzM1UzZGE2RjJPaUF3RGt1SUpmdklLcGpEeTM5SEZ5d3NZZTRfNTUyakdQejAtV2I5SWZveV9YR1NMYkdNUVBSQ2ZvcHd1V05wQ1NTaFhObnZNRjdaRFhJRzl4U2toeE5fM3YzZlhRdEZRYklycmFHbVFSMmxKM2ZvdVAxM1hxLXI0ZUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Fulcrum Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQRU0tdmVrUkpNcXE1bHJTRG9LQ1JfTDc5LW1TZVlOU05PcENseHp6LXBsLU1vMjFCYVMxcVZ5ZjQ3TUJ2UlcwcVEyLW9jVFR3Zk1wc2MwNnlfZlBtNGc4SXhzaWNNelNjUkMwV0Q0SDk3WHhzNjNDQVRXeUFzZEx3bGhZVU5GS2QxM0szV0FzQkZ2NHA0aHBPQ2ZwVDRJOWJnZEtVamN5VGUxV0hlN210YTAzNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum taps ex-Graphite Bio CEO with Oxbryta experience for board", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPZ0RmSHBqYkJHQWl4b0k2bjM3VDVmQXlXS3dmR2hOWl9tOW1zcVpWU1E2dUdwMjloWkJ1SnRUSlVvY2RKSVpFbG5xakM0b2Z6b3FhLW9pSThHVUc3NFB6S2FsbU12eGZQLWNwdEF6VUkybmwzbm9NR2NKWVl1eWhHM19iTHVycGdrMGxCcHBtTjBaSWxmNC1fNUtnX2xVaTltXzNnTmpCRHIzTXpyZEdNNzJB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE0zVlBCbHZuOGJWdEVoT0E2VzRkMUUtUWhDU3h3Z0NFQU91WWpNSV9qbmdRZFppa3FGQWRSaklfMldIZDVYVDMtTnpyaGtENXFtZlVUUGhVY3BaWXFSdGdkTEdBcWZLVFlXeHVhbVpFNnBrcHlKTS1lUW80Z1BEQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. Common Stock (FULC) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFAxV2hsbVFHQlBwYVBwamN0a1FqTlppelBPbk16NXpLS0dtTXhZS1RUSkVFbTliMWVZMVJJaWhtWXBQZXdIcXllU2tIeFFBWHpqcjRzOUxCTQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T01:33:31+00:00", "published_display": "13 Jan 2026 01:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNUDRIR2M4VTJzSzhBQ202Wm9vRERna0QySW9EMGRDdmc1Z2poY3ZzZXdOTElSQWxxdVRhNWFRTmtqeDBzWlg2YWlBYzBFVzNPMk54YXZUR3R1Q1REbzNzeHNkYldVd2FZNFlyRmtSVGd6YXZtQmRqUzFsS0poMi11RmxtbkZ5S2VVUjdXbzN1UjVydG5kV3BuLXUxVmh3Y2c0ZWFMRlpNb3pHRjkzWkNGYVBoUjNXdFhhUkRuVHNDNkNPY1J0anhXcElyR3N2NWNRLUttS0xXSDUzekJNTkE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNUUQzYU85akhVVUZ4OGNkeUNPU3FVVXNqQjJ0T0VsT1JLYTRKblhHNlp4aDNmTEZod3l2WXN1Tzdwek54SF90czUxVlM0Q1lHNjg0VWdnQkhYa2F4Rm9lbGxfejdCQnJ1anZNbHhuelBOQi04cUw0YWlsVjFZY1BxMkxB?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQajRFdWhzSmZLMWllQ0ZIenFhMUVtWlJsNXdWQnZRY24yREwybEU4cm9rZy1IRHVBeG5zME9rZDZfQndCVC1iRkp5T25JeWVXUEVOUGRnYy1NZlpRcUxNd01BaUo1Tm5IbEQ1X3dlcGRPSnpZX1h4TUVfU3d6WGQxRHR4M1M5LWV3cUF4LUl5QWpSR2hKTElHN1Bac2dxWXJtU0kyYUZKcmFWUnIyZmNUYTRlX0tIcXVYb0NlVHVWbUVZaHZ6MThsWEcyYnp0cjJ1d3dVcWxsazlUWk1UcTJsQQ?oc=5", "source_name": "Investing.com", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program due to FDA concerns about its benefit-risk profile. The FDA concluded that a", "url": "https://www.newmediawire.com/news/fulcrum-therapeutics-inc-nasdaq-fulc-faces-possible-securities-law-violations-contact-kaplan-fox-kilsheimer-llp-7087255", "source_name": "NewMediaWire", "published_at": "2026-06-20T12:39:48", "published_display": "20 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding a potential malignancy risk associated with PRC2 inhibition. Fulcrum announced it would discontinue the development", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1173566", "source_name": "ACCESS Newswire", "published_at": "2026-06-19T20:39:29", "published_display": "19 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's be", "url": "https://markets.financialcontent.com/stocks/article/thenewswire-2026-6-19-kaplan-fox-encourages-investors-of-fulcrum-therapeutics-inc-nasdaq-fulc-to-contact-the-firm", "source_name": "FinancialContent", "published_at": "2026-06-19T10:30:00", "published_display": "19 Jun 2026 10:30", "sentiment": "negative", "sentiment_pct": 10, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) are Encouraged to Contact Kaplan Fox Regarding the Investigation of Potential Securities Law Violations", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC). This investigation follows the company's announcement of discontinuing its pociredir program for sickle cell disease due to heightened FDA concerns ", "url": "https://www.newmediawire.com/news/investors-of-fulcrum-therapeutics-inc-nasdaq-fulc-are-encouraged-to-contact-kaplan-fox-regarding-the-investigation-of-potential-securities-law-violations-7087218", "source_name": "NewMediaWire", "published_at": "2026-06-18T15:12:11", "published_display": "18 Jun 2026 15:12", "sentiment": "negative", "sentiment_pct": 12, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Fulcrum Therapeutics Inc (FULC) has an earnings forecast score of 5.78, ranking 337th in the Biotechnology & Medical Research industry. Analysts have an average price target of $20.00, with a range of $5.00 to $25.00. Based on ratings from 9 analysts, the consensus is to \"Hold\" F", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fulc/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T08:40:14", "published_display": "18 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE9wQ0ZweHRoeFdUOFRzZjhXdkI1LW51ZWxLUXVJTjlzb1hkNVJiampYZTJMN0xtaGNobzJGM3ZReXhjZGRCMWxWM3AwSlRPdlFFVV9KYmE3clExX3FqS0NLbmlqMnN4bnMtalc5bGpKMFRmcEhZNHQ4?oc=5", "source_name": "TradingKey", "published_at": "2026-06-18T06:08:38+00:00", "published_display": "18 Jun 2026 06:08", "sentiment": "negative", "sentiment_pct": 5, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to an Investigation of Potential Securities Law Violations", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company announced the discontinuation of its pociredir program for sickle cell disease. This decision followed FDA concerns about the drug's ben", "url": "https://www.newmediawire.com/news/kaplan-fox-reminds-investors-of-fulcrum-therapeutics-inc-nasdaq-fulc-to-an-investigation-of-potential-securities-law-violations-7087193", "source_name": "NewMediaWire", "published_at": "2026-06-17T18:40:05", "published_display": "17 Jun 2026 18:40", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) after the company disclosed concerns from the U.S. FDA regarding a malignancy risk with its lead candidate, pociredir, leading to its discontin", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/fulcrum-therapeutics-inc.-fulc-investigation-bronstein-gewirtz-a-1173565", "source_name": "ACCESS Newswire", "published_at": "2026-06-17T11:00:00", "published_display": "17 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the major shareholder structure and institutional holdings of Fulcrum Therapeutics Inc (FULC). It lists the top individual shareholders and classifies shareholders by type, such as hedge funds and investment advisors. The report also provides a historical ove", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-fulc/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T06:11:44", "published_display": "17 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULCRUM THERAPEUTICS Investors are Encouraged to Contact Kaplan F", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations by Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after the company discontinued its pociredir program due to FDA concerns about its benefit-risk profile and malignancy risk. Following this announcement o", "url": "https://natlawreview.com/press-releases/fulcrum-therapeutics-investors-are-encouraged-contact-kaplan-fox-kilsheimer", "source_name": "The National Law Review", "published_at": "2026-06-16T23:10:33", "published_display": "16 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) securities. This investigation follows Fulcrum's disclosure that the FDA raised concerns about a potential malignancy risk with PRC2 inhibition", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/fulcrum-therapeutics-inc.-fulc-investigation-bronstein-gewirtz-a-1173563", "source_name": "ACCESS Newswire", "published_at": "2026-06-15T11:00:00", "published_display": "15 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) following the company's disclosure of FDA concerns regarding malignancy risk associated with PRC2 inhibition. Fulcrum announced the discontinuation of", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-fulcrum-ther-1173562", "source_name": "ACCESS Newswire", "published_at": "2026-06-14T11:00:00", "published_display": "14 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 14, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Fulcrum Therapeutics, Inc. (FULC) on behalf of investors. This investigation follows Fulcrum's disclosure of FDA concerns about a potential malignancy risk associated with PRC2 inhibition, leading the co", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-fulcrum-therapeuti-1173561", "source_name": "ACCESS Newswire", "published_at": "2026-06-12T16:39:12", "published_display": "12 Jun 2026 16:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (NASDAQ: FULC) adds change-in-control pay, finance chief to depart", "summary": "Fulcrum Therapeutics has implemented special retention and change-in-control protections for its remaining leadership following a major restructuring tied to discontinuing the development of pociredir for sickle cell disease. CEO Alex C. Sapir, Chief Legal Officer Curtis Oltmans,", "url": "https://www.stocktitan.net/sec-filings/FULC/8-k-fulcrum-therapeutics-inc-reports-material-event-978f654725aa.html", "source_name": "Stock Titan", "published_at": "2026-06-11T20:09:43", "published_display": "11 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Tang entities report 5,451,800\u2011share stake in Fulcrum (FULC)", "summary": "Tang Capital Management and affiliated entities have reported a combined stake of 5,451,800 shares, representing 8.2% of Fulcrum Therapeutics (FULC) common stock. This beneficial ownership involves shared voting and dispositive power among the Tang group, as detailed in a Schedul", "url": "https://www.stocktitan.net/sec-filings/FULC/schedule-13g-fulcrum-therapeutics-inc-passive-investment-disclosure-5-5d0c8a2037d8.html", "source_name": "Stock Titan", "published_at": "2026-06-10T22:39:49", "published_display": "10 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kaplan Fox is Investigating Potential Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC)", "summary": "Kaplan Fox & Kilsheimer LLP is investigating potential securities law violations against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following the discontinuation of its pociredir program for sickle cell disease. The decision came after FDA concerns regarding the drug's benefit-ris", "url": "https://www.newmediawire.com/news/kaplan-fox-is-investigating-potential-securities-law-violations-against-fulcrum-therapeutics-inc-nasdaq-fulc-7087107", "source_name": "NewMediaWire", "published_at": "2026-06-10T18:39:49", "published_display": "10 Jun 2026 18:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky", "summary": "Levi & Korsinsky, LLP is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) after its shares dropped by approximately 50% following a disclosure that the FDA raised safety concerns regarding PRC2 inhibition. The company subsequently discontinued its lead sickle cell disease ", "url": "https://www.prnewswire.com/news-releases/fulcrum-therapeutics-inc-fulc-securities-fraud-investigation---levi--korsinsky-302789808.html", "source_name": "PR Newswire", "published_at": "2026-06-10T05:40:38", "published_display": "10 Jun 2026 05:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (FULC) after the company announced it was discontinuing the development of its lead candidate, pociredir, due to FDA concerns about a potential malignancy ri", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/fulcrum-therapeutics-inc.-fulc-investigation-bronstein-gewirtz-a-1173558", "source_name": "ACCESS Newswire", "published_at": "2026-06-09T11:00:00", "published_display": "09 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum plunges after discontinuing lead program", "summary": "Fulcrum Therapeutics announced it is discontinuing the development of its lead program, losmapimod, for facioscapulohumeral muscular dystrophy (FSHD) after it failed to meet its primary endpoint in a Phase 3 trial. This decision led to a significant drop in its stock price and a ", "url": "https://www.msn.com/en-us/health/other/fulcrum-plunges-after-discontinuing-lead-program/ar-AA24DFfe?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-06-08T09:39:37", "published_display": "08 Jun 2026 09:39", "sentiment": "negative", "sentiment_pct": 13, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Fulcrum Therapeutics, Inc. (FULC)", "summary": "Levi & Korsinsky has initiated an investigation into the officers and directors of Fulcrum Therapeutics, Inc. (FULC) following a significant stock collapse. The investigation stems from the company's discontinuation of its pociredir program due to FDA safety concerns, despite pri", "url": "https://www.prnewswire.com/news-releases/fulcrum-therapeutics-inc-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-fulcrum-therapeutics-inc-fulc-302789096.html", "source_name": "PR Newswire", "published_at": "2026-06-06T07:39:18", "published_display": "06 Jun 2026 07:39", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Going On With Fulcrum Therapeutics Stock On Thursday?", "summary": "Fulcrum Therapeutics stock experienced volatility on Thursday after the company discontinued its lead experimental sickle cell disease drug, pociredir, due to FDA concerns about malignancy risks. This decision followed FDA interactions highlighting risks similar to another PRC2 i", "url": "https://www.sahmcapital.com/news/content/whats-going-on-with-fulcrum-therapeutics-stock-on-thursday-2026-06-04", "source_name": "Sahm", "published_at": "2026-06-06T03:39:49", "published_display": "06 Jun 2026 03:39", "sentiment": "negative", "sentiment_pct": 8, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks", "summary": "Fulcrum Therapeutics has discontinued its clinical-stage program for pociredir, a sickle cell disease treatment, after the FDA raised concerns about potential malignancy risks associated with its mechanism of action. This decision follows the withdrawal of Ipsen\u2019s similar drug, T", "url": "https://www.fiercebiotech.com/biotech/fulcrum-scraps-scd-program-considers-options-after-fda-takes-hard-line-safety-risks", "source_name": "Fierce Biotech", "published_at": "2026-06-05T19:10:30", "published_display": "05 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics lays off 85% of workforce as it seeks strategic alternatives", "summary": "Fulcrum Therapeutics is laying off 85% of its workforce, notifying employees on Thursday. The Cambridge biotech has enlisted Leerink Partners to explore strategic alternatives such as a merger or acquisition. This move comes as the company navigates its future options.", "url": "https://www.bizjournals.com/boston/news/2026/06/05/fulcrum-therapeutics-cuts-85-workforce.html", "source_name": "The Business Journals", "published_at": "2026-06-05T17:39:14", "published_display": "05 Jun 2026 17:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Levi & Korsinsky Announces Investigation of Securities Claims Against Fulcrum Therapeutics, Inc. (FULC)", "summary": "Levi & Korsinsky, LLP has announced an investigation into potential securities claims against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) following a significant 50% stock drop. This plunge occurred after Fulcrum disclosed that the FDA raised class-wide safety concerns about PRC2-t", "url": "https://www.globenewswire.com/news-release/2026/06/05/3307390/3080/en/levi-korsinsky-announces-investigation-of-securities-claims-against-fulcrum-therapeutics-inc-fulc.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T12:59:31", "published_display": "05 Jun 2026 12:59", "sentiment": "negative", "sentiment_pct": 10, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOcDFpNDVVUm5CYXJBN25vWmpNVEs1VW44b1JkeWZ5WGcxRXNvRkQtNWE2MEkwTnhhN0lVOWJVZUc0M0J6UjAtMWhsWmUtaW5VVUI1bmVYcnkwc0NlQWtFdWFxTWhpaExUUzBMdHAycm5UbnduRDNHaTktdFpxRHFwLTYxNF9OSlZSd2o4d3RMaGdlWmZVZ1hvVVFiWE1yV0Fy?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Fulcrum Therapeutics (FULC) Valuation After Halting Pociredir And Launching A Broad Review", "summary": "Fulcrum Therapeutics (FULC) is undergoing a significant re-evaluation after halting its sickle cell drug pociredir due to FDA concerns, leading to a 52.5% drop in share price over seven days. While some narratives suggest the stock is undervalued at $3.22, with a fair value estim", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fulc/fulcrum-therapeutics/news/a-look-at-fulcrum-therapeutics-fulc-valuation-after-halting", "source_name": "Simply Wall Street", "published_at": "2026-06-05T00:09:34", "published_display": "05 Jun 2026 00:09", "sentiment": "negative", "sentiment_pct": 35, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (FULC) cuts workforce 85% and hires Leerink for strategic review", "summary": "Fulcrum Therapeutics is undergoing a major restructuring, reducing its workforce by 85% (from 57 to 9 employees) and incurring $4.2 million in related charges, primarily due to the discontinuation of its sickle cell disease program, pociredir. The company has engaged Leerink Part", "url": "https://www.stocktitan.net/sec-filings/FULC/8-k-fulcrum-therapeutics-inc-reports-material-event-753ddc1bbccf.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:09:34", "published_display": "04 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 29, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud", "summary": "Levi & Korsinsky is investigating Fulcrum Therapeutics, Inc. (FULC) for potential securities fraud after its stock plunged approximately 50% on June 1, 2026. This drop followed the company's disclosure of FDA safety concerns related to its PRC2 inhibitor drug class, leading to th", "url": "https://www.businesswire.com/news/home/20260604159988/en/FULC-Investor-Alert-Levi-Korsinsky-Investigates-Fulcrum-Therapeutics-Inc.-FULC-for-Potential-Securities-Fraud", "source_name": "Business Wire", "published_at": "2026-06-04T19:09:34", "published_display": "04 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 5, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring", "summary": "Fulcrum Therapeutics (FULC) has shown sharp volatility after discontinuing its lead sickle cell drug, pociredir, and undergoing a major restructuring. While analysts suggest the stock is undervalued at $3.37 with a fair value of $19 based on future growth, Simply Wall St's DCF mo", "url": "https://finance.yahoo.com/sectors/healthcare/articles/look-fulcrum-therapeutics-fulc-valuation-151530350.html", "source_name": "Market source", "published_at": "2026-06-04T06:40:05", "published_display": "04 Jun 2026 06:40", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations", "summary": "SueWallSt is investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for potential securities law violations after the company's stock dropped approximately 50% following an FDA disclosure regarding class-wide safety concerns for PRC2-targeting agents, which led to the discontinu", "url": "https://www.morningstar.com/news/pr-newswire/20260603ny74176/fulc-shareholder-investigation-suewallst-investigates-fulcrum-therapeutics-inc-for-possible-securities-law-violations", "source_name": "Morningstar", "published_at": "2026-06-03T15:09:25", "published_display": "03 Jun 2026 15:09", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/jpmorgan-downgrades-fulcrum-therapeutics-underweight-112848485.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:28:48+00:00", "published_display": "03 Jun 2026 11:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug", "summary": "", "url": "https://finance.yahoo.com/m/936c99ae-f8d5-3e0a-831d-d476317640c5/fulcrum-exploring-a-potential.html", "source_name": "BioPharma Dive", "published_at": "2026-06-02T12:08:00+00:00", "published_display": "02 Jun 2026 12:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink downgrades Fulcrum Therapeutics stock rating on FDA concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQOVMyUmhWMFFXOExEZF9SVmVrbFlycnBEWHZNU081TFgxWXZaT0FkelU1elVKWGJ2RUdVekxWdC1jUTBNWXFuTlZ1ZmFrekNMX3JPQlZKNGt0dnZoRW1JLWEwS3I5X2pzMERvb1FyOU10dTR1VnFTN0lrRDdNd2VDVEYwVEhxYzZkb19PcHZzeVZXX3E2OVFsRjV3MWFhSlJvR2hONlhMM1hLekdQQU9EN0F1Vk0tNGYxWk4zdmtrbEVFOGZGTHUw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "The Economic Times", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Fulcrum Therapeutics stock collapsing today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNUk9EVUc4dl9Eb2hzWnpXeXVxbHhhRG52ZWZPWWd6cVJQQy1SVDhFY3k1OUhuYzFja25IN3gtWkRva1A5SmZXRkUzTTI5dkxnaktSUHVuajktMVZBRm96VXJ6TXJiQ2ctNUdLaFMyZlJIUFRLeG1SMGpTOE5Xeng0Ml9zTUUtOEo3YlBRRkdNY0tscEtydC1remVIZUQ3eEVfUkVjNzF4V2tuQU5QbXczSjZR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright downgrades Fulcrum stock rating on FDA concerns", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNa3pBNEhSS3hSQWRhVDdsTUF1cm8yX1pXNVlYZnpSaEFvTDI5VFQwclp1VDIwSFFacEphNWRHd3ZjbHFUaXVEbEJ0a18ydWwxbllvZjdMektjbW5NWU9xVDVyVnMwVTFUcmpjN1NEQk9Ib0RMN1IwM2xOY19wMTdTTlZJVVh3Z2R1LVY1T0FkRE5XQ3pEN1AtdW93clBJX2diTVZock02T3AzWmNvaDJqRW81bVVMeW9DYjIyNUVR?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum drops work on SCD drug pociredir; stock plummets", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOSTdYZW8xZ2R2R0RoRzBZWmNuNldHUjZheE81Y0VLWVhXYjY2bXVER1lwMkhLcWNZWVRFNjV5dTdBcXc0T2YtaWFLazVMbS04SWNpZlZpb040NFdqc1N3T3JwOTlrMmg2Z01XWnBYbGsxTXU3QjV3d1NvTHFybDhNMmFNR0prTFZKTFZkdzg0cHRjMkxvcU1qLWxmb1I?oc=5", "source_name": "BioWorld News", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FULC INVESTOR ALERT: Holzer & Holzer, LLC Investigation of Fulcrum Therapeutics, Inc.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOaUtrTTZXbU9VNlN4Umc5TUFWMVVWd1lvWDBUYm9BbUpjSll5WFFscHJ2Zl9GbGw5LVRPQ0IwUFVWbjQwRWFzVHNfeEhfUmhjams3SUlfSmpOY0p5U1dQRzk0c2c3QUhUa0M0RnFTNXc3LVllOWNOUUNTU0hEY2l6SjljTzFqa1o4dW5zTnRrR3VtREZON1hHNmdLYXA2dTQtbzFQOVo3ZEFsSTlFU2paZ3lzbUhCWHlnbFNFS0gxUWZVS2NiWmI4ZXh5bno4ZUN1UFlic3VmVl9GTDJfNkNmdnpKZlpBUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA cancer-risk stance ends sickle cell drug; Fulcrum weighs options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOakRpb1o1WXVqcThrWGdzYnp1eXlvazEyQnRpdWVWWjR5QmtkaEEtZno2SmpUN3NzSnhGZGVyaHQtbzlPa3JFQ1dYX05EZHdBOEFuNXlsc05tLTBhTTVESHRBWVRTeEZmclhDR3dQOFV0V3dBaWlmY202dU5jYmc5eDY4OWdTckU2Yld6SGJHVVpZNkkyVTlraWpQejlLQXJtUmQtaUhsVF9taUJBaXlUNTh3RGVwTWtpOWVMcjVvOA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After sickle cell data, Fulcrum plans late-2026 study", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQenF3VDk1SHhMUlhhWnhfY09TZXJOZzUya2JYV0FhMTc2TTdkWkw1RWpLdWhzM1UzZGE2RjJPaUF3RGt1SUpmdklLcGpEeTM5SEZ5d3NZZTRfNTUyakdQejAtV2I5SWZveV9YR1NMYkdNUVBSQ2ZvcHd1V05wQ1NTaFhObnZNRjdaRFhJRzl4U2toeE5fM3YzZlhRdEZRYklycmFHbVFSMmxKM2ZvdVAxM1hxLXI0ZUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] Fulcrum Therapeutics, Inc. Reports Material Event", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQRU0tdmVrUkpNcXE1bHJTRG9LQ1JfTDc5LW1TZVlOU05PcENseHp6LXBsLU1vMjFCYVMxcVZ5ZjQ3TUJ2UlcwcVEyLW9jVFR3Zk1wc2MwNnlfZlBtNGc4SXhzaWNNelNjUkMwV0Q0SDk3WHhzNjNDQVRXeUFzZEx3bGhZVU5GS2QxM0szV0FzQkZ2NHA0aHBPQ2ZwVDRJOWJnZEtVamN5VGUxV0hlN210YTAzNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum taps ex-Graphite Bio CEO with Oxbryta experience for board", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPZ0RmSHBqYkJHQWl4b0k2bjM3VDVmQXlXS3dmR2hOWl9tOW1zcVpWU1E2dUdwMjloWkJ1SnRUSlVvY2RKSVpFbG5xakM0b2Z6b3FhLW9pSThHVUc3NFB6S2FsbU12eGZQLWNwdEF6VUkybmwzbm9NR2NKWVl1eWhHM19iTHVycGdrMGxCcHBtTjBaSWxmNC1fNUtnX2xVaTltXzNnTmpCRHIzTXpyZEdNNzJB?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE0zVlBCbHZuOGJWdEVoT0E2VzRkMUUtUWhDU3h3Z0NFQU91WWpNSV9qbmdRZFppa3FGQWRSaklfMldIZDVYVDMtTnpyaGtENXFtZlVUUGhVY3BaWXFSdGdkTEdBcWZLVFlXeHVhbVpFNnBrcHlKTS1lUW80Z1BEQQ?oc=5", "source_name": "Market source", "published_at": "2026-02-12T08:00:00+00:00", "published_display": "12 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics, Inc. Common Stock (FULC) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTFAxV2hsbVFHQlBwYVBwamN0a1FqTlppelBPbk16NXpLS0dtTXhZS1RUSkVFbTliMWVZMVJJaWhtWXBQZXdIcXllU2tIeFFBWHpqcjRzOUxCTQ?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T01:33:31+00:00", "published_display": "13 Jan 2026 01:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics Announces Pricing of $175 Million Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxNUDRIR2M4VTJzSzhBQ202Wm9vRERna0QySW9EMGRDdmc1Z2poY3ZzZXdOTElSQWxxdVRhNWFRTmtqeDBzWlg2YWlBYzBFVzNPMk54YXZUR3R1Q1REbzNzeHNkYldVd2FZNFlyRmtSVGd6YXZtQmRqUzFsS0poMi11RmxtbkZ5S2VVUjdXbzN1UjVydG5kV3BuLXUxVmh3Y2c0ZWFMRlpNb3pHRjkzWkNGYVBoUjNXdFhhUkRuVHNDNkNPY1J0anhXcElyR3N2NWNRLUttS0xXSDUzekJNTkE?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-10T08:00:00+00:00", "published_display": "10 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fulcrum Therapeutics (FULC) Is Up 31.6% After $150M Stock Offering Following Positive Pociredir Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNUUQzYU85akhVVUZ4OGNkeUNPU3FVVXNqQjJ0T0VsT1JLYTRKblhHNlp4aDNmTEZod3l2WXN1Tzdwek54SF90czUxVlM0Q1lHNjg0VWdnQkhYa2F4Rm9lbGxfejdCQnJ1anZNbHhuelBOQi04cUw0YWlsVjFZY1BxMkxB?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs reiterates rating on Fulcrum Therapeutics stock after positive trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQajRFdWhzSmZLMWllQ0ZIenFhMUVtWlJsNXdWQnZRY24yREwybEU4cm9rZy1IRHVBeG5zME9rZDZfQndCVC1iRkp5T25JeWVXUEVOUGRnYy1NZlpRcUxNd01BaUo1Tm5IbEQ1X3dlcGRPSnpZX1h4TUVfU3d6WGQxRHR4M1M5LWV3cUF4LUl5QWpSR2hKTElHN1Bac2dxWXJtU0kyYUZKcmFWUnIyZmNUYTRlX0tIcXVYb0NlVHVWbUVZaHZ6MThsWEcyYnp0cjJ1d3dVcWxsazlUWk1UcTJsQQ?oc=5", "source_name": "Investing.com", "published_at": "2025-12-08T08:00:00+00:00", "published_display": "08 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 55, "sentiment_summary": {"positive": 4, "negative": 26, "neutral": 25, "score": 30, "total": 55, "label": "Cautious news tone", "tone": "negative"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 7.5, "count": 13}, {"event": "earnings", "label": "Earnings", "weight": 3.44, "count": 8}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}], "positive_events": 4, "negative_events": 26}, "market_context": {"has_market_context": true, "latest_close": 3.7, "latest_week": "2026-06-19", "one_week_move": 7.2, "four_week_move": -43.7, "twelve_week_move": -45.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.84149, "market_dynamics_buy_signal": false, "relative_strength": -63.184266, "fair_value_gap": -43.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 51.6996, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.2% over one week, -43.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Bad news being absorbed", "tone": "positive", "classification": "negative_absorbed", "summary": "Cautious headlines are being absorbed by price, which can signal underlying demand.", "confidence": 81, "badges": ["Caution agrees with inactive trend"], "opportunities": [], "risks": ["Negative tone is aligned with an inactive trend backdrop."], "event_label": "Market update", "sentiment_word": "cautious"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "Stock Titan", "count": 7}, {"label": "ACCESS Newswire", "count": 6}, {"label": "NewMediaWire", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "TradingKey", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "PR Newswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 48}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Regulatory and legal", "count": 13}, {"label": "Earnings", "count": 8}, {"label": "Deals and strategy", "count": 3}, {"label": "Analyst action", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "30/100", "tone": "negative", "text": "Cautious news tone"}, {"label": "Market reaction", "value": "Bad news being absorbed", "tone": "positive", "text": "Cautious headlines are being absorbed by price, which can signal underlying demand."}, {"label": "Primary event", "value": "Market update", "tone": "negative", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "48", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+7.2% over one week, -43.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Faces Possible Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP"}], "updated_at": "2026-06-23T01:38:33.330185+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}